

PRODUCT INFORMATION



PD 166285

Item No. 26804

CAS Registry No.: 212391-63-4

Formal Name: 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one, dihydrochloride

MF: C₂₆H₂₇Cl₂N₅O₂ • 2HCl

FW: 585.4


Purity: ≥98%

UV/Vis.: λ_{max}: 214, 263, 300, 365 nm

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PD 166285 is supplied as a solid. A stock solution may be made by dissolving the PD 166285 in the solvent of choice, which should be purged with an inert gas. PD 166285 is soluble in the organic solvent DMSO.

Description

PD 166285 is a tyrosine kinase inhibitor.¹ It inhibits Src, FGFR1, EGFR, and PDGFRβ (IC₅₀s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC₅₀ = 24 nM).^{1,2} PD 166285 inhibits PDGF- or EGF-induced receptor autophosphorylation in vascular smooth muscle cells (VSMCs) and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC₅₀s = 6.5, 1,600, and 97.3 nM, respectively).¹ It also inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC₅₀s = 80-120 nM). PD 166285 inhibits radiation-induced cell cycle arrest at the G₂/M phase and enhances radiation-induced cell death in HT-29 cells.² *In vivo*, PD 166285 (1, 5, and 10 mg/kg) inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with photodynamic therapy (PDT).³

References

1. Panek, R.L., Lu, G.H., Klutchko, S.R., *et al.* In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. *J. Pharmacol. Exp. Ther.* **283**(3), 1433-1444 (1997).
2. Wang, Y., Li, J., Booher, R.N., *et al.* Radiosensitization of p53 mutant cells by PD0166285, a novel G₂ checkpoint abrogator. *Cancer Res.* **61**(22), 8211-8217 (2001).
3. Dimitroff, C.J., Klohs, W., Sharma, A., *et al.* Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy. *Invest. New Drugs* **17**(2), 121-135 (1999).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM